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FAKCEACAM6 is a member of glycosylphosphatidylinositol-linked immunoglobulin superfamily that is implicated in
a variety of human cancers. In our previous study, we reported that CEACAM6was overexpressed in gastric can-
cer tissues and promoted cancer metastasis. The purpose of this study is to determine the role of CEACAM6 in
tumor angiogenesis andmimicry formation.We found that overexpressed CEACAM6promoted tubule formation
dependent on HUVEC cells and vasculogenic mimicry formation of gastric cancer cells; opposing results were
achieved in CEACAM6-silenced groups. Moreover, we found that mosaic vessels formed by HUVEC cells and
gastric cancer cells were observed in vitro by 3D-culture assay. Overexpressed CEACAM6 in gastric cancer cells
promoted tumor growth, VEGF expression and vasculogenic mimicry structures formation in vivo. In accordance
with these observations, we found that phosphorylation of FAK and phosphorylation of paxillin were up-
regulated in CEACAM6-overexpressing gastric cancer cells, and FAK inhibitor Y15 could reduce tubule and
vasculogenic mimicry formation. These ﬁndings suggest that CEACAM6 promotes tumor angiogenesis and
vasculogenicmimicry formation via FAK signaling in gastric cancer and CEACAM6may be a new target for cancer
anti-vascular treatment.
© 2015 Elsevier B.V. All rights reserved.1. IntroductionCarcinoembryonic antigen-related cell adhesion molecule 6
(CEACAM6), lacking transmembrane and intracellular domains, is a
glycosylphosphatidylinositol (GPI)-linked immunoglobulin super-
family member that is overexpressed in a variety of human tumors
[1–4]. CEACAM6 is co-localized to microdomains in the plasma
membrane with itself and other CEACAMs [5,6], they can form co-
clusters activating integrin signaling and its downstream signaling
cascades, such as FAK, PI3K/AKT, and MAPK [7–9]. GC is one of the
most common malignant tumors and a major health burden world-
wide [10,11]. New treatments to this malignancy are urgently
needed.
Tumor metastasis is the leading cause of cancer-related death but
its mechanisms remain unknown. Tumor angiogenesis is a crucial
aspect in the development of primary tumors or secondary tumors,
particularly when tumors diameter approximates 2 mm [12]. While
new blood vessels include not only angiogenesis formed byelated cell adhesionmolecule 6;
man umbilical vein endothelial;
+86 21 64393909.
@163.com (M. Yan).endothelial cells, but also VM tubules formed by malignant cancer
cells. VM tubule is an endothelium-independent pattern and ﬁrst
reported in melanoma study [13]. VM is strongly involved in a variety
of malignant human tumors including gastric cancer [14,15]. Red
blood cells and nutrients, contributing to cancer growth andmetastasis,
can be transferred from endothelial vessels to VM vessels. VM contrib-
utes to tumor metastasis, poor prognosis, a poor 5-year overall survival
and increases patient mortality [16,17]. However, traditional anti-
vascular treatment may contribute to the progression of cancer by
inducing hypoxia which stimulates VM formation [18]. Novel anti-
vascular therapeutic approaches to cancer should be designed. We
recently reported that CEACAM6 is up-regulated in GC tissues and
promotes GC cell metastasis via c-SRC signaling [19]. FAK signaling is
associated with tumor angiogenesis as well as cancer metastasis. The
aim of this study is to determine the role of CEACAM6 in angiogenesis
and VM formation in GC, and to explore its potential downstream
signaling targets, such as FAK signaling.
2. Materials and methods
2.1. Cell lines
The human GC cell lines SGC-7901, MKN-45, MKN-28 and human
umbilical vein endothelial (HUVEC) cells were purchased from
Shanghai Institutes for Biological Sciences, Chinese Academy of
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humidity in RPMI-1640 medium containing 10% fetal bovine serum.
2.2. Vector construction and transfection
The CEACAM6 primer sequences were 5′-CCGGAATTCCCATGGGAC
CCCCCTCAGCCC-3′ (forward) and 5′-TCCCCCGGGGCTATATCAGAGCCA
CCCTGG-3′ (reverse). Full-length CEACAM6 cDNA was obtained by
RT-PCR from total RNA extracted from GC samples. Then we assembled
a pIRES2-eGFP-CEACAM6 construct by inserting CEACAM6 cDNA into
pIRES2-eGFP vector. Moreover pIRES2-eGFP-CEACAM6 or pIRES2-
eGFP vector was transfected into SGC-7901 and MKN-45 cells using
Lipofectamine 2000 (Invitrogen, Carlsbad, USA) in accordance with
the manufacturer's protocol. Stable clones were selected by continuous
treatment with G418 (1.2 mg/ml; Gibco, New York, USA).
2.3. Lentiviral vector construction
Based on human CEACAM6 gene data, Shanghai Novobio Scientiﬁc
Co., Ltd designed and synthesized a pair of oligonucleotide sequences
and negative control sequences. shRNA sequences of CEACAM6 or
negative control were as follows: 5′-CACCGCCGGACAGTTCCATGTATA
CGAATATACATGGAACTGTCCGG-3′ (forward), and 5′-AAAACCGGACAG
TTCCATGTATATTCGTATACATGGAACTGTCCGGC-3′ (reverse); Negative
control, 5′-CACCGCTACACAAATCAGCGATTTCGAAAAATCGCTGATTTG
TGTAG-3′ (forward), and 5′-AAAACTACACAAATCAGCGATTTTTCGAAA
TCGCTGATTTGTGTAGC-3′ (reverse). CEACAM6 shRNA was subcloned
into pL/shRNA/F lentiviral vector to obtain a pL/shRNA/shR-CEACAM6
construct. Then pL/shRNA/shR-CEACAM6 or control lentiviral vector
was transfected into MKN-28, SGC-7901-CEACAM6 and MKN-45-
CEACAM6 GC cells. Stably transfected cells were selected by treatment
with 5 μg/ml blasticidin and were used for identiﬁcation and further
research.
2.4. Western blotting
Cells and tumor samples were harvested and lysed using RIPA buffer
(Solarbio, Beijing, China) containing 1% PMSF protease inhibitors. The
total protein concentration was measured by a BCA assay kit (Pierce,
Rockford, USA). Equivalent amounts of protein were separated by 10%
SDS-PAGE, and the resolved proteins transferred to PVDF membranes.
The membranes were blocked with 5% skim milk for 2 h and then
incubatedwith primary antibodies overnight at 4 °C. Primary antibodies
were as follows: CEACAM6 (9A6;1:500; Abcam, USA), paxillin (Cell
Signaling Technology (CST), USA), p-paxillin (Tyr118) (CST, USA), FAK
(CST, USA), p-FAK (Tyr925) (CST, USA), p-FAK (Tyr576/577) (CST,
USA), p-FAK (Tyr397) (CST, USA) and GAPDH (Abcam, USA). Mem-
branes were then incubated with secondary antibody for 2 h at room
temperature and were visualized using an enhanced chemilumines-
cence detection system (Amersham Bioscience, Piscataway, NJ, USA)
according to the manufacturer's protocol.
2.5. Semi-quantitative RT-PCR assay
RNA was extracted from gastric cancer cells using Trizol Reagent
(Invitrogen) according to themanufacturer's instructions. Reverse tran-
scription was performed using the reverse transcription kit (Promega,
Madision, WI, USA). Primers of CEACAM6 were 5′-TCAATGGGACGTTC
CAGCAAT-3′ (forward) and 5′-CACTCCAATCGTGATGCCGA-3′ (reverse).
Primers of GAPDH were 5′-GGACCTGACCTGCCGTCTAG-3′ (forward)
and 5′-GTAGCCCAGGATGCCCTTGA-3′ (reverse). Then PCR reactions
were carried out and the products of PCRwere separated by 2% agarose
gel (Sigma, St Louis, MO, USA). The GAPDH was used as an internal
control to verify the absence of signiﬁcant variation in the cDNA levels
in the samples.2.6. Endothelial tube formation assay
HUVEC cells were cultured in tumor supernatant with or without
FAK inhibitor 14 (1,2,4,5-benzenetetramine tetrahydrochloride
(Y15); Cayman, Michigan, USA) and plated in 96-well plate coated
with 50 μl matrigel (BD Bioscience, CA, USA) at the concentration
3 × 104 cells/well. Tumor supernatant was collected from CEACAM6-
overexpressing groups and CEACAM6-silenced groups after cultured
24 h in RPMI-1640. After 12 h incubation at 37 °C with 5% CO2, tubules
were photographed by microscopy and evaluated by Image Pro Plus
software.
2.7. Cell migration assay
For cell migration assay, a total number of 1 × 105 HUVEC cells were
added in serum-free RPMI-1640 with or without tumor supernatant
and plated in transwell chambers (8 μm for 24-well plate; Corning
Costar, NY, USA) according to the manufacturer's protocols. After 12 h
incubation, HUVEC cells were ﬁxed by 10% formalin and stained by
0.5% crystal violet. Finally, HUVEC cells in the lower chamber were
photographed and counted by inverted microscopy.
2.8. Cell proliferation assay
Cell proliferation was monitored by Cell Counting Kit-8 (CCK-8).
HUVEC cells were cultured in tumor supernatant and plated in 96-
well plate at the concentration 2000 cells/well. Cell proliferation was
measured every 24h for 5 days after adding CCK-8 2 h at the absorbance
450 nm using a Epoch Microplate Spectrophotometer (Bio Tek).
2.9. Three-dimensional (3D) culture and mosaic vessel assays
For 3D-culture and mosaic vessel assays, matrigel was thawed
overnight at 4 °C. Then 100 μl matrigel was used to coat the wells of a
24-well plate and was allowed to polymerize for 2 h at 37 °C. MKN-
45-CEACAM6, which carried with eGFP label, and HUVEC cells without
eGFP label were mixed according to 2:8 and 5:5. Tumor cells or mixed
cells (1 × 105 cells) were cultured in complete growth medium with
or without FAK Inhibitor Y15 and were plated into 24-well at the
concentration 1 × 105 cells/well. Tubules were photographed by an
AMG ﬂuorescence microscope after 24 h incubation at 37 °C with
5% CO2 and were evaluated by Image Pro Plus software.
2.10. VM assay
Serum-free RPMI-1640medium andmatrigel weremixed according
to 2:1. The mixture was then seeded onto 16 mm glass cover slides in
6-well plate and was allowed to polymerize for 2 h at 37 °C. Then
1 × 105 GC cells were seeded onto each plate and cultured for 3 days
at 37 °Cwith5%CO2.Moreover, GCswereﬁxed by4%paraformaldehyde
and stained by PAS stain according to the manufacturer's protocols.
After counterstained with hematoxylin, slides were dehydrated and
covered.
2.11. Immunohistochemical and histochemical double-staining methods
Sections of 4 μm thick were cut from parafﬁn-embedded nude mice
tumor and human cancer tissue blocks and then deparafﬁnized and
rehydrated. Immunohistochemical staining of sections was performed
according to the DAKO protocol, using primary antibody mouse anti-
CEACAM6 (1:100; Abcam), primary antibody rabbit anti-VEGF (1:100;
Abcam) and mouse anti-CD34 (1:100; Santa Cruz Biotechnology) at
37 °C for 2 h. After stained by anti-CD34 and visualized by diaminoben-
zidine, sections were incubated with PAS (Leagene, Beijing, China)
according to the protocol. CD34 positive vessels indicated blood vessels
in tissues, and CD34 negative, PAS positive vessels were deﬁned as VM.
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SGC-7901-CEACAM6 and SGC-7901-NC (1 × 106 cells) were
subcutaneously injected into 4-week-old male BALB/c nude mice
(Institute of Zoology, China Academy of Sciences). Tumor nodules
were measured every 7 days, and were calculated using the formula:
tumor volume = (Width2 × Length) / 2. Mice were killed 5 weeks
after injection. Tumors were weighed and ﬁxed for immunohisto-
chemistry staining.
2.13. Statistical analysis
Data are shown as mean ± SD. Differences between experimental
groups were assessed by the Student's t test or one-way ANOVA. AFig. 1. Effect of CEACAM6 on tubular formation in vitro. (A) Overexpression and suppression of
bules were observed in the SCG-7901-CEACAM6 and MKN-45-CEACAM6 groups compared w
groups formed less tubules than the SCG-7901-CEACAM6/nc and MKN-45-CEACAM6/nc gr
(D) and mean tubular lengths (E) between different groups. *P b 0.05; **P b 0.01. Data are reptwo-tailed value of P b 0.05 was considered statistically signiﬁcant.
Statistical analyses were performed using IBM SPSS 19.0 software
(SPSS Inc).
3. Results
3.1. CEACAM6 promotes tubular formation of HUVEC cells
CEACAM6 overexpression and knockdown in GC cells were
conﬁrmed by western blotting and RT-PCR (Fig. 1A; Fig. S1.A). Then
tumor supernatant was collected from SGC-7901-CEACAM6, SGC-
7901-CEACAM6/sh, MKN-45-CEACAM6, MKN-45-CEACAM6/sh, MKN-
28-CEACAM6/sh and their control groups to culture HUVEC cells. Thirty
thousand HUVEC cells were plated into 96-well plate coated withCEACAM6 in GC cells were conﬁrmed at the protein level by western blotting. (B) Rich tu-
ith the control groups; whereas the SCG-7901-CEACAM6/sh and MKN-45-CEACAM6/sh
oups (200×). (C–E) Bar charts show numbers of tubules (C), numbers of intersections
resented as mean ± SD of three independent experiments.
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increased tubules forming ability in CEACAM6-overexpressing groups
compared with the control groups (Fig. 1B), such as the number of
tubules (Fig. 1C), number of intersections (Fig. 1D), and mean length
of tubules (Fig. 1E). Opposing results were achieved in CEACAM6-
silenced groups compared with the control groups (Fig. 1, Fig. S1.C).
3.2. CEACAM6 promotes HUVEC cell proliferation and migration
Tubule formation of HUVEC cells was correlated with HUVEC cell
proliferation and migration. After HUVEC cells incubating in tumor
supernatant for 24 h, HUVEC cell proliferation was increased in
CEACAM6-overexpressing groups and decreased in CEACAM6-silenced
groups compared with control groups (Fig. 2A, B). A similar tendency
with HUVEC cell proliferation was observed in HUVEC cell migration.
The migration ability of HUVEC cells was enhanced in CEACAM6-
overexpressing groups and inhibited in CEACAM6-silenced groups
compared with control groups (Fig. 2C, D; Fig. S1.D). Thus, these results
suggested CEACAM6 promoted tumor angiogenesis in GC by stimulat-
ing HUVEC cell proliferation and migration.
3.3. CEACAM6 promotes VM formation in GC cells
VM tubules were deﬁned as vessels formed by malignant tumor
cells, which was different from blood vessels formed by HUVEC cells.
More VM structures were observed in CEACAM6-overexpressing
groups than the control groups (Fig. 3A). The opposing result was
obtained in CEACAM6-silenced groups compared with the control
groups (Fig. 3A; Fig. S1.B). And the VM forming ability was evaluatedFig. 2. Effects of CEACAM6onmigration and proliferation of HUVECs. The tumor supernatant fro
sh and their control groups was collected to treat HUVEC cells, and we next examined the mi
CEACAM6-overexpressing groups compared with the control groups, and opposing result w
migration of HUVECs, whereas silenced CEACAM6 reduced the migration of HUVECs (200×)
represented as mean ± SD of three independent experiments.by the number of tubules (Fig. 3B), number of intersections (Fig. 3C),
and mean length of tubules (Fig. 3D).
Furthermore, to illustrate the effect of CEACAM6 on VM in GC cells,
another assay, periodic acid-Schiff (PAS) staining, was performed. As
well as 3D-culture assay, PAS staining showed overexpressed CEACAM6
promoted VM formation in GC cells (Fig. 4). In conclusion, CEACAM6
could enhance the VM forming ability of GC cells.
3.4. GC cells and HUVEC cells form mosaic vessels in vitro
Nutrition for tumor growth is supplied by HUVEC and VM vessels.
Mosaic vessels serve as a bridge to transfer nutrition for HUVEC and
VM vessels. To verify that mosaic vessels exist in vitro, GC cells were
mixed with HUVEC cells according to the proportion 2:8 and 5:5 at
the total number 1 × 105, then the mixture cells were plated into
24-well plate coated with matrigel. GC cells labeled with eGFP showed
green image under the ﬂuorescence microscope (Fig. 5A). However,
HUVEC cells without eGFP showed gray image under the ﬂuorescence
microscope (Fig. 5B). Mosaic vessels were observed in the mixture
cells composed of GC cells and HUVEC cells according to the proportion
2:8 (Fig. 5C) and 5:5 (Fig. 5D). These ﬁndings conﬁrmed that GC cells
and HUVEC cells were able to form mosaic vessels to supply nutrition
for tumor growth.
3.5. CEACAM6 upregulates phosphorylated FAK and paxillin in GC cells
FAK signaling is associated with tumor angiogenesis as well as
cancermetastasis. Our previous study showed that CEACAM6promoted
GC metastasis in vivo and in vitro [19]. In this study, overexpressedmSCG-7901-CEACAM6, SCG-7901-CEACAM6/sh,MKN-45-CEACAM6,MKN-45-CEACAM6/
gration and proliferation of HUVECs. (A, B) The proliferation of HUVECs was increased in
as observed in CEACAM6-silenced groups. (C) Overexpressed CEACAM6 promoted the
. (D) Histograms showed the numbers of migration cells. *P b 0.05; **P b 0.01. Data are
Fig. 3. Effect of CEACAM6 on VM in GC cells on matrigel. (A) More vessel-like structures deﬁned as VMwere formed in CEACAM6-overexpressing groups, on the contrary the converse
results were observed in CEACAM6-silenced groups compared with the control groups, respectively (200×). The numbers of tubules (B), numbers of intersections (C) and mean tubular
lengths (D) between different groups. *P b 0.05; **P b 0.01. Data are represented as mean ± SD of three independent experiments.
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Tyr576/577, and Tyr397 phosphorylation of FAK and phosphorylation
of paxillin (Tyr118) (Fig. 6B, C). Opposing results were observed in
CEACAM6-silenced groups compared with control groups (Fig. 6A, B,
C).Meanwhile, we found that p-FAKwas increased in humanGC tissues
which overexpressed CEACAM6 (Fig. S2.C). Interestingly, tubule and
VM formation was decreased after treated with FAK inhibitor Y15 in
SGC-7901-CEACAM6 GC cells. Collectively, these ﬁndings suggested
that CEACAM6 promoted tumor angiogenesis and VM formation via
FAK signaling.
3.6. CEACAM6 promotes tumorigenesis and VM in vivo
The effect of CEACAM6 on tumorigenesis was examined by subcuta-
neously injecting SGC-7901-NC and SGC-7901-CEACAM6 GC cells into
nude mice. We observed that overexpressed CEACAM6 promoted
tumor growth compared with the control groups (Fig. 7A). The average
tumor volume was much larger in CEACAM6-overexpressing groups
than that in control groups (Fig. 7B). Moreover, the weight of tumors
was increased in SGC-7901-CEACAM6 groups compared with the
control groups (1.55±0.18 g vs 1.05±0.22 g, P b 0.05; Fig. 7C). Enough
nutrition and red blood cells from increasing vessels may be the
interpretation about the above ﬁndings.
Furthermore, tumor sections from nude mice mold were stained
by VEGF and CD34/PAS double staining. We observed that VEGF
expression was increased in SGC-7901-CEACAM6 groups comparedwith SGC-7901-NC groups (Fig. 7D). And more VM structures with
or without red blood cells were observed in SGC-7901-CEACAM6
groups compared with SGC-7901-NC groups (Fig. 7E, F). The IHC
showed that more CD34 positive expression was obtained in GC
tissues than in non-tumor tissues (Fig. S2.B). This tendency was
congruity with CEACAM6 expression in GC samples (Fig. S2.A).
Meanwhile, the level of p-FAK (397) extracted from tumor of nude
mice was increased in SCG-7901-CEACAM6 groups compared with
the control groups. These ﬁndings in vivo were consistent with the
results in vitro. These results suggested that CEACAM6 promoted
gastric tumor growth via stimulating VM formation in vivo.
4. Discussion
We recently reported that CEACAM6 is overexpressed in GC tissues
and promotes GC tumor invasion and migration [19]. It is important to
note that although CEACAM6 lacks transmembrane and intracellular
domains, it does regulate a variety of signaling pathways promoting
cancer metastasis, anoikis resistance, chemoresistance, and inhibiting
differentiation [3,19–22]. Cancer metastasis is correlated with tumor
angiogenesis. Based on these observations, the purpose of this study is
to determine the role of CEACAM6 in mediating tumor angiogenesis
and VM formation in GC.
Interestingly, we observed that CEACAM6 promoted tubule forma-
tion dependent on HUVEC cells in this study. As an attempt to under-
stand the events which promoted tubule formation via CEACAM6,
Fig. 4. Effect of CEACAM6 on VM in GC cells by PAS staining. (A) PAS staining was performed to examine VM structures in GC cells. Consistent with the GC cells tubule formation on
matrigel, more PAS positive VM structures were detected in CEACAM6-overexpressing groups compared with the control groups. However, the VM structures of CEACAM6-silenced
groups were less than the control groups (200×). Histograms showed the numbers of tubules (B) and mean tubular lengths (C) between different groups. *P b 0.05; **P b 0.01. Data
are represented as mean ± SD of three independent experiments.
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HUVEC cells incubating in tumor supernatant.We found that CEACAM6
was able to promote HUVEC cell proliferation and migration. The
increasing proliferation and migration of HUVEC cells contributed to
tubule formation in GC. HUVEC cells do not express CEACAMs. How
can CEACAM6 promote tubule HUVEC cell proliferation and migration?
Thus, there must be some factors, secreted by GC cells, in tumor super-
natant to stimulate proliferation and migration of HUVEC cells rather
than CEACAM6 interacts with HUVEC cells, although they remain
unclear. Additionally, VM structures, an endothelium-independent pat-
tern, increased in CEACAM6-overexpressing groups than in CEACAM6-
silenced groups. Twomethods were performed in this study to conﬁrm
this ﬁnding in GC. Both 3D-culture and PAS staining assays showed that
CEACAM6 promoted VM formation in GC cells. The existence of VM
structure is one phenotype of a malignant cancer. Furthermore, with
the increasing tubule formation and VM structures in CEACAM6-
overexpressing GC cells, nutrients were enough to be supplied for
tumor growth. Consist with this inference, tumor volume and weight
derived from CEACAM6-overexpressing groups were increased com-
paredwith the control groups in vivo. More interestingly,mosaic vessels
were observed by mixing HUVEC and GC cells in vitro. This conﬁrmed
that nutrients and red blood cells could be transferred in VM vesselsformed by GC cells as well as in tubules formed by HUVEC cells. These
could strongly promote the progression of GC.
VM indicates a poor prognosis and deﬁnes highly invasive cancer
phenotype. VEGFR-2 played a key role in VM formation in human
glioblastomas [23]. In our study, we observed VEGF expression was
increased in CEACAM6-overexpressing groups by nude mice tumor
immunochemistry. To better understand a mechanism for how these
processes could be regulated by CEACAM6, FAK a cytoplasmic tyrosine
kinase, affecting cell survival, cell growth, angiogenesis, cellular inva-
sion, and cellular migration [24–26], was detected in this study. Phos-
phorylation of FAK was increased in highly aggressive melanoma
cancer cells than poorly aggressive cells, and increased FAK activity
promoted VM and metastasis in melanoma [27,28]. FAK promoted
tumor angiogenesis through the promotion of brain endothelial cell
migration in malignant astrocytic tumors [25]. In accordance with
these observations, we found that overexpressed CEACAM6 in GC cells
and tissues increased phosphorylation of FAK and its downstream
phosphorylation of paxillin. Additionally, the proliferation and migra-
tion of HUVEC cells were increased in CEACAM6-overexpressing groups
and decreased in CEACAM6-silenced groups. Furthermore, the tyrosine
397, an autophosphorylation site of FAK, could be inhibited by Y15
inhibitor and is important in its downstream signaling functions.
Fig. 5. GC cells and HUVECs formmosaic vessels on matrigel. (A) MKN-45-CEACAM6 GC cells with eGFP label formed VM onmatrigel. (B) The tubules of HUVEC cells without eGFP label
showed gray image under green light. (C)MKN-45-CEACAM6GC cellsmixedwithHUVEC cells according to 2:8 (total cells 1 × 105) onmatrigel.Mosaic vesselswere observed under green
light. (D) To clearly examine themosaic vessels, MKN-45-CEACAM6GC cells mixedwith HUVEC cells according to 5:5 (total cells 1 × 105) onmatrigel (400×). Green image: GC cells; gray
image: HUVEC cells. Three independent experiments were performed.
Fig. 6. CEACAM6 regulates FAK signaling in GC cells. (A) Overexpression of CEACAM6 in GC cells was conﬁrmed at the RNA level by RT-PCR. (B) Phosphorylated FAK and paxillin were
increased in CEACAM6-overexpressing groups compared with the control groups. (C) Histograms showed the phosphorylated FAK and paxillin ratio. Total FAK and paxillin as a loading
control. (D) FAK inhibitor Y15 10 μM decreased tubule and VM formation (200×). Three independent experiments were performed.
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Fig. 7. Effects of CEACAM6 on tumor growth and VM in vivo. (A) Photographs of xenografts tumors of SGC-7901-NC and SGC-7901-CEACAM6. (B) Tumor volumes were measured every
7 days (P b 0.01). (C) Averageweights of tumors in nudemice (P b 0.05). (D) Expression of VEGF in nudemice by immunohistochemistry (400×). (E) VM channels (black arrow) with or
without red blood cells (red arrow) formed by GC cells were stained by CD34/PAS double staining (200×). (F) Histograms showed the numbers of VM tubules; *P b 0.05. More VM
structures were observed in SGC-7901-CEACAM6 groups than SGC-7901-NC groups. (G) Protein p-FAK (397) extracted from tumor of nude mice was increased in SCG-7901-CEACAM6
groups compared with the control groups.
1027M. Zang et al. / Biochimica et Biophysica Acta 1852 (2015) 1020–1028Interestingly, we observed that Y15 decreased tubules and VM forma-
tion in CEACAM6-overexpressing GC cells. These ﬁndings suggested
that CEACAM6 promoted GC angiogenesis and VM formation, at least
in part, via FAK signaling. Moreover, we found that in our present
study CEACAM6 induced epithelial–mesenchymal transition (EMT),
which contributes to VM formation [29]. Collectively, CEACAM6
promoted angiogenesis and VM formation in gastric cancer via FAK
signaling.
In conclusion, CEACAM6 promoted GC metastasis in our previous
study [19] and stimulated tumor angiogenesis and VM formation in
this study. These ﬁndings suggested that CEACAM6 may serve as a
marker in GC deﬁning cancer as a highly aggressive phenotype. As
these effects of CEACAM6, we may identify a new avenue based on
CEACAM6 for the GC therapy.
Supplementary data to this article can be found online at http://dx.
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